Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Leeuwen, F. E.
Right arrow Articles by Aleman, B. M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Leeuwen, F. E.
Right arrow Articles by Aleman, B. M. P.
Journal of Clinical Oncology, Vol 18, Issue 3 (February), 2000: 487
© 2000 American Society for Clinical Oncology

Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood

By Flora E. van Leeuwen, Willem J. Klokman, Mars B. van’t Veer, Anton Hagenbeek, Augustinus D. G. Krol, Ursula A. O. Vetter, Michael Schaapveld, Peter van Heerde, J. Marion V. Burgers{dagger}, Reinier Somers, Berthe M. P. Aleman

From the Departments of Epidemiology, Medical Oncology, Radiotherapy, and Pathology, the Netherlands Cancer Institute, Amsterdam, and Departments of Hematology and Radiotherapy, Dr Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
{dagger} Deceased.

Address reprint requests to Flora E. van Leeuwen, PhD, Department of Epidemiology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands; email fvleeuw{at}nki.nl

PURPOSE: To quantify the long-term risk of second primary cancers (SCs) in patients diagnosed with Hodgkin’s disease (HD) during adolescence or young adulthood.

PATIENTS AND METHODS: The risk of SCs was assessed in 1,253 patients diagnosed with HD before the age of 40 years and treated in two Dutch cancer centers between 1966 and 1986. The median follow-up duration was 14.1 years.

RESULTS: In all, 137 patients developed SCs, compared with 19.4 cases expected on the basis of incidence rates in the general population (relative risk [RR] = 7.0; 95% confidence interval, 5.9 to 8.3). The 25-year actuarial risk of SC overall was 27.7%. The RR of solid tumors increased greatly with younger age at the first treatment of HD, not only for breast cancer but also for all other solid tumors, with RRs of 4.9, 6.9, and 12.7 for patients first treated at ages 31 to 39 years, 21 to 30 years, and <= 20 years, respectively.

Among patients first treated at the age of 20 years or younger, the RR of developing a solid tumor before the age of 40 years was significantly greater than the RR of solid tumor development at ages 40 to 49 years (RR = 27.9 v RR = 4.2; P = .0001). Patients who received salvage chemotherapy had significantly greater risk of solid cancers other than breast cancer than did patients whose treatment was restricted to initial radiotherapy or initial combined-modality treatment (RR = 9.4 and 4.7, respectively; P = .004).

CONCLUSION: After more than 20 years of follow-up, the risk of solid tumors is still much greater in survivors of HD than in the population at large. Reassuringly, the greatly increased risk of solid tumors in patients who were young (<= 20 years of age) at the first treatment seems to decrease as these patients grow older. Our data suggest that chemotherapy may increase the risk of solid tumors from radiotherapy.




This article has been cited by other articles:


Home page
 Ann OncolHome page
S. H. Yang, K. H. Yang, Y. P. Li, Y. C. Zhang, X. D. He, A. L. Song, J. H. Tian, L. Jiang, Z. G. Bai, L. F. He, et al.
Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials
Ann. Onc., June 1, 2008; 19(6): 1039 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Ronckers, M. M. Doody, J. E. Lonstein, M. Stovall, and C. E. Land
Multiple Diagnostic X-rays for Spine Deformities and Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 605 - 613.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Lee, M. Pintilie, D. C. Hodgson, P. E. Goss, and M. Crump
Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma
Ann. Onc., January 1, 2008; 19(1): 62 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. K. Ng
Second Cancers after Hodgkin's Lymphoma: Long-term Risks
ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. De Bruin, J. Huisbrink, M. Hauptmann, M. A. Kuenen, G. M. Ouwens, M. B. van't Veer, B. M. P. Aleman, and F. E. van Leeuwen
Treatment-related risk factors for premature menopause following Hodgkin lymphoma
Blood, January 1, 2008; 111(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema, S. Horenblas, M. W.J. Louwman, J. G. Ribot, H. J. Hoekstra, G. M. Ouwens, B. M.P. Aleman, and F. E. van Leeuwen
Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
J. Clin. Oncol., October 1, 2007; 25(28): 4370 - 4378.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. T. Armstrong, C. A. Sklar, M. M. Hudson, and L. L. Robison
Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter?
J. Clin. Oncol., October 1, 2007; 25(28): 4477 - 4489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al.
Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial
J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Guerin, M. Hawkins, A. Shamsaldin, C. Guibout, I. Diallo, O. Oberlin, L. Brugieres, and F. de Vathaire
Treatment-Adjusted Predisposition to Second Malignant Neoplasms After a Solid Cancer in Childhood: A Case-Control Study
J. Clin. Oncol., July 1, 2007; 25(19): 2833 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al.
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. M. P. Aleman, A. W. van den Belt-Dusebout, M. L. De Bruin, M. B. van 't Veer, M. H. A. Baaijens, J. P. d. Boer, A. A. M. Hart, W. J. Klokman, M. A. Kuenen, G. M. Ouwens, et al.
Late cardiotoxicity after treatment for Hodgkin lymphoma
Blood, March 1, 2007; 109(5): 1878 - 1886.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ng and P. Mauch
The impact of treatment on the risk of second malignancy after Hodgkin's disease
Ann. Onc., December 1, 2006; 17(12): 1727 - 1729.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al.
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
Ann. Onc., December 1, 2006; 17(12): 1749 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. T. Meadows
Pediatric Cancer Survivorship: Research and Clinical Care
J. Clin. Oncol., November 10, 2006; 24(32): 5160 - 5165.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. M. Noordijk, P. Carde, N. Dupouy, A. Hagenbeek, A. D.G. Krol, J. C. Kluin-Nelemans, U. Tirelli, M. Monconduit, J. Thomas, H. Eghbali, et al.
Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials
J. Clin. Oncol., July 1, 2006; 24(19): 3128 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Das, A. K. Ng, C. C. Earle, P. M. Mauch, and K. M. Kuntz
Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis
Ann. Onc., May 1, 2006; 17(5): 785 - 793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. F. Koontz, J. P. Kirkpatrick, R. W. Clough, R. G. Prosnitz, J. P. Gockerman, J. O. Moore, and L. R. Prosnitz
Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications
J. Clin. Oncol., February 1, 2006; 24(4): 605 - 611.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. J. Schonfeld, E. S. Gilbert, G. M. Dores, C. F. Lynch, D. C. Hodgson, P. Hall, H. Storm, A. Andersen, E. Pukkala, E. Holowaty, et al.
Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients
J Natl Cancer Inst, February 1, 2006; 98(3): 215 - 218.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al.
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, B. Klimm, T. Schmitz, L. Wildt, V. Diehl, and A. Engert
Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol., October 20, 2005; 23(30): 7555 - 7564.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. B. Travis, D. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, E. Pukkala, C. F. Lynch, et al.
Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
J Natl Cancer Inst, October 5, 2005; 97(19): 1428 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Lavoie, J. M. Connors, G. L. Phillips, D. E. Reece, M. J. Barnett, D. L. Forrest, R. D. Gascoyne, D. E. Hogge, S. H. Nantel, J. D. Shepherd, et al.
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
Blood, August 15, 2005; 106(4): 1473 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. P. Canellos
Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option
J. Clin. Oncol., July 20, 2005; 23(21): 4574 - 4576.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Das, A. K. Ng, M. A. Stevenson, and P. M. Mauch
Clinical course of thoracic cancers in Hodgkin's disease survivors
Ann. Onc., May 1, 2005; 16(5): 793 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Pentheroudakis and N. Pavlidis
Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology
Ann. Onc., February 1, 2005; 16(2): 181 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Rueda Dominguez, A. Marquez, J. Guma, M. Llanos, J. Herrero, M. A. de las Nieves, J. Miramon, and E. Alba
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study
Ann. Onc., December 1, 2004; 15(12): 1798 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Straus, C. S. Portlock, J. Qin, J. Myers, A. D. Zelenetz, C. Moskowitz, A. Noy, A. Goy, and J. Yahalom
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
Blood, December 1, 2004; 104(12): 3483 - 3489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. M. Hudson, M. Krasin, M. P. Link, S. S. Donaldson, C. Billups, T. E. Merchant, L. Kun, A. L. Billet, S. Kaste, N. J. Tarbell, et al.
Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease
J. Clin. Oncol., November 15, 2004; 22(22): 4541 - 4550.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. B. Kenney, Y. Yasui, P. D. Inskip, S. Hammond, J. P. Neglia, A. C. Mertens, A. T. Meadows, D. Friedman, L. L. Robison, and L. Diller
Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Ann Intern Med, October 19, 2004; 141(8): 590 - 597.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Behringer, A. Josting, P. Schiller, H. T. Eich, H. Bredenfeld, V. Diehl, and A. Engert
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group
Ann. Onc., July 1, 2004; 15(7): 1079 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. M. P. Aleman, N. S. Russell, H. Bartelink, and F. E. van Leeuwen
Re: Radiation Therapy in the Treatment of Hodgkin's Disease--Do You See What I See?
J Natl Cancer Inst, February 4, 2004; 96(3): 235 - 236.
[Full Text] [PDF]

Home page
 JCOHome page
V. Diehl
Chemotherapy or Combined Modality Treatment: The Optimal Treatment for Hodgkin's Disease
J. Clin. Oncol., January 1, 2004; 22(1): 15 - 18.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology, January 1, 2004; 2004(1): 184 - 202.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Takagi, R. Tsuchida, K. Oguchi, T. Shigeta, S. Nakada, K. Shimizu, M. Ohki, D. Delia, L. Chessa, Y. Taya, et al.
Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease
Blood, January 1, 2004; 103(1): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Engert, P. Schiller, A. Josting, R. Herrmann, P. Koch, M. Sieber, F. Boissevain, M. de Wit, J. Mezger, E. Duhmke, et al.
Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol., October 1, 2003; 21(19): 3601 - 3608.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M.P. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, M. B. van't Veer, H. Bartelink, and F. E. van Leeuwen
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease
J. Clin. Oncol., September 15, 2003; 21(18): 3431 - 3439.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. B. Travis, D. A. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, T. Wiklund, C. F. Lynch, et al.
Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
JAMA, July 23, 2003; 290(4): 465 - 475.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. L. Longo
Radiation Therapy in the Treatment of Hodgkin's Disease--Do You See What I See?
J Natl Cancer Inst, July 2, 2003; 95(13): 928 - 929.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. E. van Leeuwen, W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. P. Aleman, A. Broeks, M. Gospodarowicz, et al.
Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease
J Natl Cancer Inst, July 2, 2003; 95(13): 971 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
J. S. Welsh, S. A. Thurman, and S. P. Howard
Thymoma and Multiple Malignancies: A Case of Five Synchronous Neoplasms and Literature Review
Clin. Med. Res., July 1, 2003; 1(3): 227 - 232.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. M.P. Aleman, J. M.M. Raemaekers, U. Tirelli, R. Bortolus, M. B. van 't Veer, M. L.M. Lybeert, J. J. Keuning, P. Carde, T. Girinsky, R. W.M. van der Maazen, et al.
Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma
N. Engl. J. Med., June 12, 2003; 348(24): 2396 - 2406.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Foss Abrahamsen, A. Andersen, O. Nome, A. B. Jacobsen, H. Holte, J. Foss Abrahamsen, and S. Kvaloy
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
Ann. Onc., November 1, 2002; 13(11): 1786 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Ng, M. V. P. Bernardo, E. Weller, K. Backstrand, B. Silver, K. C. Marcus, N. J. Tarbell, M. A. Stevenson, J. W. Friedberg, and P. M. Mauch
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors
Blood, August 28, 2002; 100(6): 1989 - 1996.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. M. Dores, C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, F. E. van Leeuwen, E. J. Holowaty, et al.
Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years
J. Clin. Oncol., August 15, 2002; 20(16): 3484 - 3494.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Diller, C. M. Nancarrow, K. Shaffer, U. Matulonis, P. Mauch, D. Neuberg, N. J. Tarbell, H. Litman, and J. Garber
Breast Cancer Screening in Women Previously Treated for Hodgkin's Disease: A Prospective Cohort Study
J. Clin. Oncol., April 15, 2002; 20(8): 2085 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Duhmke, J. Franklin, M. Pfreundschuh, S. Sehlen, N. Willich, U. Ruhl, R.-P. Muller, P. Lukas, A. Atzinger, U. Paulus, et al.
Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin's Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone
J. Clin. Oncol., June 1, 2001; 19(11): 2905 - 2914.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. P. Neglia, D. L. Friedman, Y. Yasui, A. C. Mertens, S. Hammond, M. Stovall, S. S. Donaldson, A. T. Meadows, and L. L. Robison
Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study
J Natl Cancer Inst, April 18, 2001; 93(8): 618 - 629.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Metayer, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, T. Joensuu, F. E. van Leeuwen, M. B. van't Veer, R. E. Curtis, et al.
Second Cancers Among Long-Term Survivors of Hodgkin's Disease Diagnosed in Childhood and Adolescence
J. Clin. Oncol., June 12, 2000; 18(12): 2435 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Aisenberg, D. M. Finkelstein, F. E. van Leeuwen, W. J. Klokman, and B. M. P. Aleman
Second Malignancies in Hodgkin's Disease
J. Clin. Oncol., May 10, 2000; 18(10): 2186 - 2187.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online